Recently, it has been found that PANDAR, as a novel tumor-associated lncRNA, exhibits abnormal expression in several cancers including gastric cancer (GC), colorectal cancer (CRC), renal cell carcinoma (RCC), bladder cancer (BC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), non-small cell lung cancer (NSCLC), and other cancers (17–21, 32, 33, 52, 53). This evidence concerns the gene PANDAR and urinary bladder carcinoma.